Special Issue "PROTAC—From Bench to Bed"
A special issue of Medicines (ISSN 2305-6320).
Deadline for manuscript submissions: 31 January 2023.
Interests: medicinal chemistry; chemical biology; organic chemistry
Proteolysis targeting chimera (PROTAC) technology was developed to artificially induce the degradation of a given protein of interest by hijacking the ubiquitin–proteasome system through a bifunctional molecule. PROTACs were first reported in 2001 and have witnessed rapid development in the past two decades. Many of those bifunctional molecules have been utilized to uncover biology mechanisms as probes, and several Phase I clinical trials have been launched to evaluate the most advanced PROTAC molecules against cancer-related diseases. Compared to traditional small molecules, PROTACs can be more selective with equal potency. However, due to the chemical nature of the protein degrader, achieving molecules with satisfied DMPK properties remains a challenge. This Special Issue will tap into the cutting-edge research development of PROTACs on new targets and PROTACs showing good DMPK properties or animal study results. Biological mechanistic studies using PROTACs as a probe or research studies focusing on PROTAC druggability optimization and pharmacology studies are also welcome.
Dr. Deyao Li
Dr. Ke li
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- PROTAC technology
- Protein degradation
- Drug development
- Clinical research